Astellas Pharma Inc. (ALPMY,ALPMY) reported first … .0 billion yen. Basic core earnings per share is now projected … 1.8 trillion yen. Basic earnings per share is anticipated to … .93 yen. For more earnings news, earnings calendar, and earnings for stocks, visit …

Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2023 … for joining our FY 2023 earnings call, despite your busy schedule … 'm Naoki Okamura from Astellas Pharma Inc. Thank you very much … to close today's earnings calls. Thank you very much …

… Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last released its quarterly earnings data … Ideas? (Get Free Report) Astellas Pharma Inc manufactures, markets, and imports … analysts' ratings for Astellas Pharma and related companies with MarketBeat …

… Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last released its earnings … that Astellas Pharma will post 0.32 earnings per … share for the current year. About Astellas Pharma … (Get Free Report) Astellas Pharma Inc manufactures, markets, and …

… .91. Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last announced its earnings results … analysts forecast that Astellas Pharma will post 0.32 earnings per share for … the current fiscal year. Astellas Pharma Company …

… its second quarter 2024 earnings with a mix of … the FibroGen Second Quarter 2024 Earnings Conference Call. All participants … to our second quarter 2024 earnings call. On today… our partnerships with AstraZeneca and Astellas Pharma. Due to strong roxadustat …

… its second quarter 2024 earnings with a mix of … the FibroGen Second Quarter 2024 Earnings Conference Call. All participants … to our second quarter 2024 earnings call. On today… our partnerships with AstraZeneca and Astellas Pharma. Due to strong roxadustat …

… . IRWD reported break-even earnings for the second quarter of … Zacks Consensus Estimate of earnings of 17 cents per … company had recorded adjusted earnings of 31 cents per share … agreements with two partners — Astellas Pharma and AstraZeneca AZN — related …

- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple …

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ( …